

SKYEPHARMA PLC  
Form 6-K  
September 02, 2005

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of September, 2005

SkyePharma PLC

---

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

---

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

---

## Edgar Filing: SKYEPHARMA PLC - Form 6-K

### DATE OF RELEASE OF INTERIM RESULTS FOR THE SIX MONTHS ENDING 30 JUNE 2005 UPDATE ON FLUTIFORM NEGOTIATIONS

LONDON, UK, 2 September 2005 - SkyePharma plc (LSE: SKP, NASDAQ: SKYE) will announce its Interim results for the six months ending 30 June 2005 on Wednesday 28 September 2005. These results will be the first presented in accordance with International Financial Reporting Standards.

SkyePharma announced at the end of April that it had negotiated Heads of Terms with a major global pharmaceutical company for the US rights to Flutiform. SkyePharma has now discontinued contract negotiations with this company. However, as indicated in July, the April announcement created considerable competitive interest in Flutiform. As a result, SkyePharma remains in active negotiations with several companies, including discussions with another major global pharmaceutical company for worldwide rights to Flutiform.

Michael Ashton, SkyePharma's Chief Executive, said: "Flutiform's prospects continue to improve and its profile will make it superior to competing products in this fast-growing market, already valued at over \$5 billion. A number of companies remain actively interested in licensing the product, with various commercial structures including the retention of co-promotion rights by SkyePharma. Progress towards filing the New Drug Application remains on track and Phase III trials are planned to commence early next year. With estimated peak sales well in excess of \$1 billion, we remain convinced of our ability to deliver significant value to shareholders."

#### For further information please contact:

SkyePharma PLC +44 207 491 1777

Michael Ashton, Chief Executive Officer +44 207 491 5124  
Peter Laing, Director of Corporate Communications +1 212 753 5780  
Sandra Haughton, US Investor Relations

Buchanan Communications +44 207 466 5000

Tim Anderson / Mark Court / Rebecca Skye Dietrich

#### Notes for editors:

##### About SkyePharma

SkyePharma develops pharmaceutical products benefiting from world-leading drug delivery technologies, including easier-to-use and more effective drug formulations. There are now eleven approved and marketed products using SkyePharma's technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information, visit [www.skyepharma.com](http://www.skyepharma.com).

##### About Flutiform

Flutiform is a fixed-dose combination of the inhaled corticosteroid fluticasone with the long-acting beta<sub>2</sub>-agonist bronchodilator formoterol in an HFA-powered metered-dose aerosol inhaler. Flutiform, which is used for the treatment of asthma and chronic obstructive pulmonary disease (COPD), has completed Phase II clinical trials.

*Certain statements in this news release are forward-looking statements and are made in reliance on the safe harbor provisions of the U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the information reflected in these forward-looking statements are reasonable, it can give no assurance that these statements will materialize. Because the expectations are subject to risks and uncertainties, actual results may differ from those expressed or implied by the forward-looking statements based upon a number of factors, including: changes in SkyePharma's 20-F and other documents on file with the SEC. Factors that could cause differences between actual results and those implied by the forward-looking statements contained in this news release include: regulatory approval, limitation, risks related to the development of new products, risks related to obtaining and maintaining regulatory approval for existing, new or expanded indications of existing and new products, risks related to manufacturing, ability to manufacture products on a large scale or at all, risks related to SkyePharma's and its partners' ability to market products on a large scale to maintain or expand market share in the face of changing customer requirements, competition and technological change, risks related to regulatory compliance, product liability claims, risks related to the ownership and use of intellectual property, and risks related to SkyePharma's ability to manage growth. SkyePharma undertakes no obligation to revise or update any forward-looking statements.*

Edgar Filing: SKYEPHARMA PLC - Form 6-K

*statement to reflect events or circumstances after the date of this release.*

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**SkyePharma PLC**

By: /s/ Douglas Parkhill

Name: Douglas Parkhill

Title: Company Secretary

Date: September 2, 2005